Clinical use of [TIMP-2]•[IGFBP7] biomarker testing to assess risk of acute kidney injury in critical care: guidance from an expert panel.
Louis M GuzziTobias BerglerBrian BinnallDaniel T EngelmanLui ForniMichael J GermainEric GluckIvan GöczeMichael JoannidisJay L KoynerV Seenu ReddyThomas RimmeléClaudio RoncoJulien TextorisAlexander ZarbockJohn A KellumPublished in: Critical care (London, England) (2019)
In the experience of our expert panel, biomarker testing has been a priority after major surgery, hemodynamic instability, or sepsis. Our panel members reported that a positive test prompts management of nephrotoxic drugs as well as fluids, while patients with negative results are considered to be excellent candidates for "fast-track" protocols.